The 24th of September 2024 is the last day of trading in warrants of series TO 1, which were issued in connection with Diagonal Bio AB’s (“Diagonal Bio” or the “Company”) preferential rights issue of units that was carried out earlier in 2024. The exercise period runs until the 26th of September 2024.
Read moreToday is the first day for the exercise of Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) warrants of series TO 1 (“TO 1”) which were issued in connection with the preferential issue of units that the Company carried out earlier this year. The period lasts until June 26, 2024. Holders of TO 1 have the right to subscribe for one (1) new share in Diagonal Bio for each TO 1 at a price of SEK 0,05 per share. Through full utilisation of TO 1, the Company will receive approximately SEK 2,25 million before issue costs. An information document is available on the respective websites of Diagonal Bio (www.diagonalbio.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).
Read moreDiagonal Bio’s platforms using an 8-parallel test format, show overall Accuracy of 99.6 %, Sensitivity of 100 %, and Specificity of 99.5 %.
Read moreDiagonal Bio AB (publ) (“Diagonal Bio” or the “Company”) today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company’s founders with extensive experience and knowledge within the company’s market areas. The agreement means that Diagonal Bio is supported by Källstrand’s long experience and deep knowledge to strengthen its go-to-market strategy.
Read moreNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) issue of units consisting of shares and consideration free warrants of series TO 1 (”TO 1”), with preferential right for the Company’s existing shareholders begins. The subscription period runs until the 22[nd] of April 2024. The issue volume initially amounts to a maximum of approximately SEK 32 million before transaction costs (the “Rights Issue”). Upon full subscription of the Rights Issue and full utilization of issued TO 1 at the highest subscription price, the Company may receive an additional approximately SEK 9.5 million before transaction costs. The Rights Issue is secured in writing by members of the board, management, existing shareholders, and external investors to a total of approximately 56.4 percent (corresponding to approximately SEK 18 million) through pre-subscription and guarantee commitments. A prospectus is available via the Company’s (www.diagonalbio.com), Sedermera Corporate Finance AB’s (www.sedermera.se) and Nordic Issuing AB’s (www.nordic-issuing.se) websites. The Company’s will today, the 8[th] of April 2024, present at an event with Financial Stockholm at Scandic Klara Hotell.
Read more
Scheelevägen 17
223 63 Lund
Sweden
Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com
Svensk Kapitalmarknadsgranskning AB
www.skmg.se
Phone: +46 (0)8 913 008
E-mail: ca@skmg.se
Nordic Issuing AB
Stortorget 3
211 22 Malmö
